lansoprazole / Generic mfg. - LARVOL DELTA

Evaluation of the Safety and Efficacy of K-CAB (Tegoprazan) as Symptomatic Maintenance Therapy in Patients With NERD: A Multicenter, Randomized Double-Blinded Controlled Trial. (PubMed, Korean J Helicobacter Up Gastrointest Res) - "Both treatments were well tolerated, with no serious adverse events reported. These findings suggest that alternate-day tegoprazan offers comparable efficacy and safety to daily lansoprazole therapy and may serve as a more flexible and patient-friendly maintenance option for NERD."

Clinical • Journal • Gastroenterology • Gastroesophageal Reflux Disease

CD20 Allergic contact dermatitis due to a rosary necklace. (PubMed, Br J Dermatol) - "The patient had a past medical history of hay fever, hypertension and recurrent cold sores, and took antihypertensives, antivirals and lansoprazole...A search conducted on PubMed and Google Scholar was unable to find any further case reports reporting this. Future work to elucidate the allergens within O. porosa should be completed, as well as its sensitizing capacity."

Journal • Allergic Rhinitis • Allergy • Atopic Dermatitis • Cardiovascular • Contact Dermatitis • Dermatitis • Dermatology • Hypertension • Immunology • CD20

Encapsulation-based enhancements in modern drug delivery systems. (PubMed, Int J Pharm) - "In addition, the pharmaceutical industry has commercialized many encapsulated drugs, such as anti-inflammatory (ibuprofen, dexamethasone), high blood pressure drugs (valsartan, azilsartan), proton pump inhibitors (lansoprazole), anti-cancer (carboplatin, carmustine, cisplatin, trastuzumab, cytarabine, paclitaxel, doxorubicin (DOX), vincristine) antiparasitic (amphotericin), antifungal (clotrimazole), and hormonal (melatonin (MLT))). It can render drugs more convenient and user-friendly for various therapeutic purposes and help to enhance their performance, functionality, and effectiveness. This comprehensive review examines the encapsulation technologies employed in the pharmaceutical industry, highlighting notable examples of encapsulated drugs that demonstrate their mechanism of action and potential therapeutic effects in vitro, in vivo, and through clinical trials, with relevance to various diseases."

Journal • Review • Cardiovascular • Hypertension • Oncology

IMpALA: A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer (clinicaltrials.gov) - P2 | N=0 | Withdrawn | Sponsor: The Christie NHS Foundation Trust | N=42 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Breast Cancer • Hormone Receptor Negative Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • ER • HER-2 • PGR

Evaluation of the Safety of Lansoprazole Exposure During Early Pregnancy: A Prospective Cohort Study Using Two-Center Counseling Data in Japan. (PubMed, Yakugaku Zasshi) - "The results indicate that lansoprazole exposure during the first trimester is not associated with an increased risk of major malformations. Overall, our findings provide valuable insight for selecting gastroesophageal reflux disease medications for use in pregnant women."

Journal • Gastroenterology • Gastroesophageal Reflux Disease

Association between exposure to proton pump inhibitors and hypertension: a descriptive and disproportionality analysis of VigiBase. (PubMed, BMJ Open) - "This investigation indicates a notable pharmacovigilance safety signal associating PPI usage with hypertension reporting. Although a potential dose-response trend was observed, it was not statistically significant, possibly due to limited statistical power. Further longitudinal studies are warranted."

Journal • Cardiovascular • Gastrointestinal Disorder • Hypertension

Proton pump inhibitors and the risk of urolithiasis: A Mendelian randomization study. (PubMed, Medicine (Baltimore)) - "The genome-wide association studies (GWAS) of Omeprazole, Esomeprazole, Lansoprazole, and Rabeprazole medication can be obtained from GWAS catalog. In conclusion, our results suggest a causal relationship of PPIs to UL. For patients requiring antiacid therapy, esomeprazole may be a better option than Rabeprazole, especially in patients with high-risk factors for urolithiasis."

Journal • Renal Calculi • Urolithiasis

Efficacy of Vonoprazan in Nonsteroidal Anti-Inflammatory Drug-Induced Ulcer in Terms of Ulcer Recurrence and Gastrointestinal Bleeding: A Systematic Review and Meta-Analysis. (PubMed, Gastroenterol Res Pract) - "The GRADE of evidence was moderate. Vonoprazan could significantly reduce the risk of ulcer recurrence and gastrointestinal bleeding as compared to lansoprazole in patients with NSAID-induced ulcers."

Journal • Retrospective data • Review • Gastroenterology • GAST • PGC

Vonoprazan attenuates proteinuria in diabetic kidney disease through potential direct renal mechanism. (PubMed, Sci Rep) - "Additionally, vonoprazan-treated patients showed significant improvement in eGFR after 3 months compared to baseline levels (p < 0.05), with this improvement being superior to that observed with lansoprazole (p < 0.05). Vonoprazan may have a direct renal effect, warranting further research to elucidate its mechanism in reducing albuminuria."

Clinical • Journal • Diabetes • Diabetic Nephropathy • Infectious Disease • Metabolic Disorders • Nephrology • Renal Disease

Class effects of proton pump inhibitors in preventing oxaliplatin-induced peripheral neurotoxicity. (PubMed, J Pharmacol Sci) - "Basic research has revealed that omeprazole, a proton pump inhibitor (PPI), exerts preventive effects against OIPN...Notably, esomeprazole, lansoprazole, and rabeprazole, classified as PPIs, prevented oxaliplatin-induced cultured F11 neuronal cell damage, and repeated PPI administration prevented mechanical allodynia in rats. However, vonoprazan, a potassium ion-competitive acid blocker, did not exert such effects. Overall, our results highlight the class effects of PPIs against OIPN."

Journal • Pain

Single-cell-level digital twins for preterm birth prevention strategies. (PubMed, bioRxiv) - "Tetrahydrofolate, maprotiline, and the combination of aspirin and lansoprazole emerged as top candidates for PTL prevention, delaying labor onset primarily through enhanced mTOR signaling in innate immune cells and attenuated JAK/STAT signaling in naïve CD4⁺ T cells. The codebase is available at https://github.com/ofondeur/SIMCO/ ."

Journal • CD4

Integrative pharmacovigilance and AI-based framework uncovers potential drug triggers in juvenile idiopathic arthritis. (PubMed, Front Immunol) - "Among these, lansoprazole and aripiprazole showed strong signals in both pharmacovigilance and DMPNN predictions. This multi-level convergence supports the hypothesis that certain non-antirheumatic drugs may aggravate JIA-like inflammation, particularly within the systemic subtype. In this study, we identify lansoprazole as a likely instigator of systemic juvenile idiopathic arthritis, underscoring that proton-pump inhibitors should be used judiciously in children at autoimmune risk and providing a generalizable playbook for rare-disease pharmacovigilance."

Adverse events • Journal • Idiopathic Arthritis • Immunology • Inflammation • Pediatrics • Rare Diseases • Rheumatology • IL6

RJYYQKLY-04: Efficacy of Gut-Brain Neuromodulators in the Treatment of Gastroesophageal Reflux Disease (clinicaltrials.gov) - P=N/A | N=164 | Completed | Sponsor: RenJi Hospital | Active, not recruiting ➔ Completed | N=120 ➔ 164

Enrollment change • Trial completion • Gastroenterology • Gastroesophageal Reflux Disease

Collagenous gastritis, hyperplastic polyp, and intraepithelial duodenal lymphocytosis in a 15-year-old child: An iconographic case report. (PubMed, Medicine (Baltimore)) - "In consideration of a colon-rectal cancer diagnosis of his father at the age of 45 years, we carried out a Search Tool for the Retrieval of Interacting Genes/Proteins and Pymol-based Protein Data Bank study and found that interleukin-4 may be the key factor supporting the occurrence of hyperplastic polyps in collagenous gastritis."

Journal • Colon Cancer • Colorectal Cancer • Fatigue • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Immunology • Oncology • Rectal Cancer • Solid Tumor • IL4

Immediate reactions to proton pump inhibitors: Clinical findings and testing outcomes. (PubMed, Allergol Immunopathol (Madr)) - "İmmediate hypersensitivity reactions are observed among PPIs, particularly to lansoprazole, with the majority of reactions being anaphylaxis. Multiple life-threatening reactions can be prevented by increasing awareness of allergies to PPIs. Cross-reactivities among PPIs are variable, and further studies are needed to elucidate cross-reactivity with PPIs."

Journal • Allergy • Immunology

Helicobacter pylori eradication and associated factors: dual therapy versus standard triple therapy in Lima, Peru (PubMed, Rev Gastroenterol Peru) - "The H. pylori eradication rate with dual therapy was superior to standard triple therapy. The proton pump inhibitor with the highest eradication rate was esomeprazole. There were no significant differences in eradication according to sex, age, or comorbidities."

Journal • Cardiovascular • Diabetes • Dyslipidemia • Gastric Cancer • Hypertension • Infectious Disease • Metabolic Disorders • Oncology • Solid Tumor

Loss of SMPDL3b Induces Podocytopathy and Nephrotic Syndrome via Dysregulation of Cytidine Diphosphate (CDP)-Choline Metabolism and Store-Operated Calcium (Ca2+) Entry (KIDNEY WEEK 2025) - "The therapeutic effects of phosphocholine were blocked by pre-treatment with Lansoprazole (a phosphocholine phosphatase inhibitor), implicating choline as the active product...Conclusion Taken together, our findings demonstrate that SMPDL3b is essential for maintaining podocyte structural and functional integrity. Loss of SMPDL3b may induce podocytopathy via disrupted CDP-choline metabolism, reduced choline signaling, and aberrant Ca 2+ influx through Orai1 channels."

Glomerulonephritis • Nephrology • Renal Disease • STIM1

Proton pump inhibitors-induced thrombocytopenia: A systematic literature analysis of case reports. (PubMed, Open Med (Wars)) - "The PPIs associated with thrombocytopenia included pantoprazole (11 cases), lansoprazole (4 cases), omeprazole (2 cases), and esomeprazole (1 case). Clinicians should enhance their awareness when evaluating potential cases of thrombocytopenia. Once PPIs are suspected, immediate discontinuation of the drugs and initiation of appropriate treatments are recommended."

Journal • Hematological Disorders • Thrombocytopenia

Comparative Effectiveness of Vonoprazan vs Lansoprazole in Treating Erosive Esophagitis: A Meta-Analysis of Randomized Controlled Trials (ACG 2025) - "Eight randomized controlled trials were included in the final analysis. Vonoprazan demonstrated comparable efficacy to lansoprazole in achieving endoscopic healing of erosive esophagitis within 4–8 weeks [RR: 1.03 (0.99–1.07); P=0.10; I²=70%]. However, vonoprazan significantly reduced EE recurrence at 24–48 weeks compared to lansoprazole [RR: 0.46 (0.25–0.86); P=0.01; I²=76%]."

HEOR • Retrospective data • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • GAST

ACG- a Forgotten Hematemesis Syndrome (ACG 2025) - "Endoscopy showed hemorrhagic, erythematous, and prolapsing mucosa in the stomach body.Case 2: A 66-year-old man with GERD (on lansoprazole), treated Hepatitis C, and daily cannabis use had four days of nausea, vomiting, and hematemesis with clots...Early recognition helps guide treatment to control vomiting and prevent mucosal injury. Although bleeding is often self-limited, prompt diagnosis improves outcomes.Figure: ACGFigure: ACG"

ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Depression • Dermatology • Dyslipidemia • Dyspepsia • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Hematological Disorders • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Psychiatry • Rare Diseases

Potassium-Competitive Acid Blockers Versus Proton Pump Inhibitors in Patients With Grade C and D Erosive Esophagitis: A Meta-Analysis (ACG 2025) - "Six RCTs involving 2,836 patients (1,433 receiving PCABs and 1,403 receiving PPIs) were included from 1,208 citations. The studies evaluated Vonoprazan, Zastaprazan, and Fexuprazan (PCABs), and Lansoprazole and Esomeprazole (PPIs). In the subgroup analysis of four studies comparing vonoprazan 20 mg with lansoprazole 30 mg, vonoprazan demonstrated significantly higher healing rates at both 4 and 8 weeks: RR 1.12 (95% CI: 1.03 – 1.21, p = 0.005) at 4 weeks, and RR 1.12 (95% CI: 1.01 – 1.24, p = 0.005) at 8 weeks."

Retrospective data • Gastrointestinal Disorder

Systematic Review: Comparison Between Proton Pump Inhibitors and Vonoprazan in Management of Gastric Ulcers, Helicobacter Gastritis, Gastroesophageal Reflux Disease and Post-Procedure Bleeding (ACG 2025) - "For GERD, VPZ is statistically superior to Rabeprazole but not with Esomeprazole, lansoprazole, and omeprazole. Results showed no statistically significant difference in the ulcer healing rate at week 2, 4, 6, and 8. The most effective regimen for treating peptic ulcer disease appears to be lansoprazole 30 mg at both 2 and 8 weeks. At the 4-week mark, pantoprazole 40 mg outperformed vonoprazan 20 mg in terms of efficacy."

Review • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Infectious Disease • Inflammation • Peptic Ulcer

Efficacy of Vonoprazan versus Lansoprazole in Erosive Esophagitis: A Systematic Review and Meta-Analysis (ACG 2025) - "Six randomized controlled trials with a total of 3,655 patients were included. Both vonoprazan 10 mg and 20 mg significantly reduced the risk of EE recurrence at 24 weeks compared to lansoprazole, with odds ratios of 0.44 and 0.33 (p = .001 and p = .002, respectively), and the effect was more pronounced with the 20 mg dose. In the induction phase, both doses of vonoprazan were also associated with significantly higher healing rates than lansoprazole (OR 1.51 and 1.87; p = .001 and p < .001, respectively), with greater benefit observed at 20 mg."

Retrospective data • Review • Gastrointestinal Disorder

Sexual Dysfunctions Associated with Proton Pump Inhibitors: Insights from VigiBase, the World Health Organization Pharmacovigilance Database. (PubMed, Drug Saf) - "Findings of this study suggest the presence of safety signals of PPI-induced sexual dysfunctions, such as erectile dysfunction, genital discomfort and oestrogen deficiency. However, further observational studies are required to validate and further characterise these potential safety signals."

Adverse events • Journal • Endocrine Disorders • Erectile Dysfunction • Sexual Disorders

Targeting fatty acid synthase to overcome PARP inhibitor resistance and to create an artificial synthetic lethality for triple-negative breast cancer. (PubMed, Genes Dis) - "In this study, we show that FASN contributes to PARPi resistance, and that lansoprazole and 5HLS strongly synergize with olaparib and talazoparib in both BRCA1-mutant and wild-type TNBC cells. 5HLS also facilitates PARPi-induced PARP1 trapping and inhibits BRCA1 expression by inhibiting FASN, contributing to the synergy with PARPi in both BRCA1 wild-type and mutant TNBC cells. Together, these findings suggest that inhibiting FASN with PPIs creates an artificial synthetic lethality, providing a rationale for combining PPIs with PARPi to expand their utility to TNBC patients without germline BRCA1 mutations and to overcome PARPi resistance."

IO biomarker • Journal • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • BRCA • BRCA1 • BRCA2 • FASN • HER-2